<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198536</url>
  </required_header>
  <id_info>
    <org_study_id>ISTA-ECBT-CS01</org_study_id>
    <nct_id>NCT00198536</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome</brief_title>
  <official_title>Efficacy and Safety of Ecabet Ophthalmic Solution (2.83% and 3.70%) for Treatment of Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ecabet ophthalmic solution is an effective
      treatment for dry eye syndrome
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular discomfort</measure>
    <time_frame>Day 91</time_frame>
    <description>Group mean change in ocular discomfort score from pre-Cataract extraction (CAE) to post-CAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear Film Break-up Time (TFBUT)</measure>
    <time_frame>Day 91</time_frame>
    <description>Group mean change in time to tear break-up from pre-CAE to post-CAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blink Rate</measure>
    <time_frame>Day 91</time_frame>
    <description>Group mean change in blinks/min from pre-CAE to post-CAE.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Ecabet 2.83%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ecabet 3.70%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop of vehicle in study eye 4 times daily for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ecabet 2.83%</intervention_name>
    <arm_group_label>Ecabet 2.83%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ecabet 3.70%</intervention_name>
    <arm_group_label>Ecabet 3.70%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agree to avoid systemic &amp; topical ophthalmic meds &amp; disallowed meds

          -  Have a best corrected visual acuity (BCVA) of 20/40 with pinhole or better in each eye

          -  Diagnosis of moderate dry eye syndrome

        Exclusion Criteria:

          -  Uncontrolled ocular or systemic disease that could interfere with study

          -  Diagnosis of Sjogren's syndrome, lacrimal obstruction, reflex, lid-related or contact
             lens-related dry eye syndrome(DES); significant anterior blepharitis or meibomianitis

          -  Contraindications or hypersensitivity to use of study meds or components

          -  Wear contact lenses

          -  Secondary dry eye to surgery

          -  Eye surgery (including laser) within 6 months

          -  Use of systemic or topical ophthalmic meds within 14 days

          -  Punctal plugs in one or both eyes in place for &lt;45 days

          -  Permanent occlusion of the lacrimal puncta
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim McNamara, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>ISTA Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Maine Eye Care</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eyesight Ophthalmic Services, PA</name>
      <address>
        <city>Dover</city>
        <state>New Hampshire</state>
        <zip>03820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Ecabet</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

